

News Release

Corona del Mar, CA --- July 14, 2013



ImmunogenX formed to develop advanced diagnostics and screening tools for celiac disease

Company is committed to improving quality of life

ImmunogenX™ has completed registration as a California Limited Liability Company (Immunogenics LLC) dedicated to developing advanced diagnostics and screening tools for celiac disease management and for accurately measuring gluten and other allergen content in foods for those also suffering from food allergies. The only recourse to recovery for individuals suffering from celiac disease is a life-long adherence to a gluten-free diet. The company was founded by Dr. Jennifer A. Sealey-Voyksner who serves as Chief Technology Officer and Dr. Jack A. Syage who serves as Chief Executive Officer and is supported by a team of world-renowned clinicians, scientists and advisors.

ImmunogenX disease management and food safety technology is strongly building on advanced new diagnostics based on liquid chromatography mass spectrometry for which the principles of the company are recognized as leading experts and innovative leaders.

For disease management we are extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there are no other effective non-intrusive diagnostics.

For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

The company corporate headquarters are in Corona del Mar, CA and the laboratory facilities are in Durham, NC in Research Triangle Park.

www.Immunogenx.com

For further information please contact

Jack A. Syage, PhD
CEO
714 357-0631
jsyage@immunogenx.com